Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 1 of the last 4 fiscal years.
-
Tight liquidity NBB
Cash and receivables cover 1 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
ESTRELLA CLINICAL RESEARCH from Herentals, company number BE0737730926, closed financial year 2025 with a result of € -10,112 after tax. For that financial year ESTRELLA CLINICAL RESEARCH recorded a gross margin of € 7,486 and equity of € -8,112. Compared with financial year 2024, the result moved from € 1,231 to € -10,112. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on June 18, 2026.
€ -8,112
▼ € 10,112 vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -10,112
▼ still € 1,231 profit in 2024
Profit after tax over the fiscal year.
€ 135
▼ € 30,666 vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -10,112.
People and assets in 2025
≈ 1
No payroll staff. One director, so that person most likely runs the business.
€ 39,744
▼ 28% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 41,836
▼ 25% vs 2024
€ 14,632 is repaid this year. At this pace the long-term loan is gone in ≈ 3 years.
€ 1,161
▼ 49% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 647
▼ 90% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 156,285 | € 132,543 | € 22,166 | € 7,486 | ▼ 66% |
| Profit after taxes | € 122,535 | € 97,288 | € 1,231 | € -10,112 | ▼ € 11,343 |
| Equity | € 4,938 | € 36,715 | € 2,000 | € -8,112 | ▼ € 10,112 |
| Total debts | € 201,665 | € 87,173 | € 100,453 | € 49,593 | ▼ 51% |
| Cash | € 43,942 | € 36,442 | € 30,801 | € 135 | ▼ € 30,666 |
| Retained profit | € 2,938 | € 34,715 | € 0 | € -10,112 | |
| Dividend | € 290,000 | € 65,510 | € 35,946 | € 0 | ▼ 100% |
| Bank debt | € 15,204 | € 69,241 | € 55,839 | € 41,836 | ▼ 25% |
| Balance sheet total | € 206,603 | € 123,888 | € 102,453 | € 41,482 | ▼ 60% |
Key figures of ESTRELLA CLINICAL RESEARCH, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to ESTRELLA CLINICAL RESEARCH?
What happened at ESTRELLA CLINICAL RESEARCH in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 10,112 (▼ € 11,343 vs 2024). Source: NBB ↗
- New establishment in Herentals. KBO
- Pieter VAN LEEMPUTTE became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 122,535 profit in 2022 to € 10,112 loss in 2025.
Paid € 65,467 in corporate taxes since 2022.
Best year ever: 2022, with € 122,535 profit.
Paid out € 391,457 in dividends to the owners in total.
A new publication or filing at ESTRELLA CLINICAL RESEARCH? We notify you, reason included.
Follow ESTRELLA CLINICAL RESEARCHDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind ESTRELLA CLINICAL RESEARCH is Pieter VAN LEEMPUTTE.
Directors
According to the 2025 annual accounts
Pieter VAN LEEMPUTTE
Director
since 2019
Establishments
Establishment units
Physical locations of this company
Korte Akker(MRH) 6
2200 Herentals
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0737.730.926
- VAT number
- BE 0737.730.926
- Registered office
- Korte Akker(MRH) 6, 2200 Herentals
- Names & denominations
- ESTRELLA CLINICAL RESEARCH
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 15 November 2019
- Peppol
- Active · Active since 1 Jun 2025
- Activities · NACE
Vervaardiging van farmaceutische grondstoffen
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Overige activiteiten van vrije beroepen en andere wetenschappelijke en technische activiteiten, neg
Activiteiten van medische beeldvorming en medische laboratoria
Overige gespecialiseerde wetenschappelijke en technische activiteiten
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Activiteiten van medische laboratoria